Skip to Content

Garenoxacin FDA Approval Status

FDA Approved: No
Generic name: Garenoxacin
Company: Schering-Plough Corporation
Treatment for: Bacterial Infection

Garenoxacin is an investigational broad-spectrum quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections.

In August 2006, Schering-Plough Corporation announced the withdrawal of the New Drug Application (NDA) for garenoxacin.

Development Timeline for Garenoxacin

Feb 13, 2006Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.